4.5 Article

The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations

期刊

RESPIRATORY MEDICINE
卷 109, 期 12, 页码 1546-1552

出版社

W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2015.10.011

关键词

COPD; CAT; Exacerbations

资金

  1. Boehringer Ingelheim
  2. Pfizer
  3. AstraZeneca
  4. Chiesi
  5. GlaxoSmithKline
  6. Menarini
  7. Teva
  8. Boehringuer Ingelheim
  9. Almirall
  10. Esteve
  11. Gebro Pharma
  12. CLS Behring
  13. Medilmmune
  14. Takeda
  15. Grifols
  16. Novartis

向作者/读者索取更多资源

Introduction: Since exacerbations of chronic obstructive pulmonary disease (COPD) cause both a great impact on the progression of the disease and generate high health expenditures, there is a need to develop tools to evaluate their prognosis. Method: Multicenter, observational, prospective study that evaluated the prognostic utility of the COPD Assessment Test (CAT) in severe exacerbations of COPD. Anthropometric and clinical variables were analyzed: smoking, history of exacerbations during the previous year, drug treatment, degree of baseline dyspnea, comorbidities; laboratory variables at admission (complete blood count, arterial blood gas and biochemistry) and CAT scores in the first 24 h of admission, on the third day, at discharge and at 3 months. Results: We evaluated 106 patients (91 males) with a mean age of 71.1 (SD 9.8 years), mean FEV1 45.2% (14.7%) and average CAT score at admission of 24.7 points (7.1). At three months after discharge, treatment failure was observed in 39 (36.8%) patients: 14 (13.2%) presented an exacerbation without the need for hospital admission, 22 were readmitted (20.8%) and 3 (2.8%) died during follow-up. The three factors associated with increased risk of failure were a reduction less than 4 units in the CAT at discharge compared to admission, lower hemoglobin levels and treatment with domiciliary oxygen. Conclusions: A change of <= 4 points in the CAT score at discharge compared to that obtained at admission due to a severe exacerbation of COPD, helps to predict therapeutic failure such as a new exacerbation, readmission or death in the subsequent three months. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据